According to IMARC Group latest report titled “Psoriatic Arthritis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on psoriatic arthritis treatment market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global psoriatic arthritis treatment market size reached US$ 9.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.8 Billion by 2032, exhibiting a growth rate (CAGR) of 9.2% during 2024-2032.

Request a Sample Request: https://www.imarcgroup.com/psoriatic-arthritis-treatment-market/requestsample

Psoriatic Arthritis Treatment Market Overview:

Psoriatic arthritis is a chronic autoimmune disease characterized by inflammation of the skin and joints, affecting individuals with psoriasis. The treatment for psoriatic arthritis aims to manage symptoms, reduce inflammation, prevent joint damage, and improve quality of life. These treatments range from pharmaceuticals, such as nonsteroidal anti-inflammatory drugs (NSAIDs), to advanced biologic therapies that target specific pathways in the immune system. The properties of these treatments include their ability to modulate the immune response, reduce the signs and symptoms of the disease, and slow its progression. The working mechanism involves either suppressing the overactive immune system or blocking the action of specific molecules involved in the inflammatory process. The advantages of these treatments lie in their potential to significantly alleviate symptoms, improve joint function, and prevent further joint degradation, allowing patients to maintain a more active and comfortable lifestyle.

Psoriatic Arthritis Treatment Market Trends:

The global market is primarily driven by the growing awareness and diagnosis rates of psoriatic arthritis among the global population. In line with this, advancements in biologic and targeted synthetic DMARDs (Disease-Modifying Antirheumatic Drugs) are providing an impetus to the market. Moreover, the increasing adoption of personalized medicine approaches is acting as a significant growth-inducing factor for the market. In addition to this, the expanding geriatric population, more prone to psoriatic arthritis due to age-related susceptibility, is resulting in a higher demand for effective treatment options. Besides this, the rising prevalence of psoriasis as a primary condition leading to psoriatic arthritis is creating lucrative opportunities in the market. Also, the growing investment in research and development activities by pharmaceutical companies to innovate and develop more effective treatment solutions is impacting the market positively. The market is further driven by the implementation of favorable healthcare policies and the availability of reimbursement scenarios, making treatments more accessible to patients. Apart from this, increased healthcare spending across developed and developing regions is propelling the market. Some of the other factors contributing to the market include the expanding role of biologics in the treatment paradigm, the growing awareness of early diagnosis and treatment benefits, and the increasing number of clinical trials focusing on identifying new therapeutic targets and treatment modalities.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/psoriatic-arthritis-treatment-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eisai Co. Ltd.
• Eli Lilly and Company
• Johnson & Johnson Service ltd.
• Novartis AG
• Pfizer Inc.
• Samsung Biologics
• UCB S.A.

Psoriatic Arthritis Treatment Market Segmentation:

Our report has categorized the market based on drug type, type, route of administration and distribution channel.

Breakup by Drug Type:

• NSAIDs (Nonsteroidal Anti-Inflammatory drugs)
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Biologics
• Others

Breakup by Type:

• Prescription
• OTC

Breakup by Route of Administration:

• Injectable
• Oral
• Topical

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Breakup by Region:

• North America (USA, Canada)
• Europe (Germany, France, UK, Italy, Spain, Russia, others)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, others)
• Middle East/Africa
• Latin America (Brazil, Mexico, others)

Key Highlights of the Report:

• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

About US:

IMARC Group is a leading market research firm that provides management strategy and market research worldwide. We work with clients in every sector and geography to identify their most valuable opportunities, address their most important challenges and transform their businesses.

The IMARC Group's information offerings include key market trends, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high technology sectors. Market forecasts and industry analysis in biotechnology, advanced materials, pharmaceuticals, food and beverages, travel and tourism, nanotechnology and innovative processing methods are among the company's top areas of expertise.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163